EGFR and non-small cell lung carcinoma: The discovery in 2004 that a subset of NSCLC patients with EGFR‐activated mutations showed a dramatic clinical response to the first‐generation EGFR‐TKI Gefitinib ushered in the era of targeted therapy in NSCLC [47, 48, 49].